Treatment of @entity1072 with XXXX : a phase II study using strict response criteria.

@entity1 @entity137 @entity42870 @entity882 @entity548 @entity1072 @entity5805 @entity281 @entity1398 @entity617
Twenty-one @entity1 with @entity1072 ( @entity1072 ) were entered into this Northern California Oncology Group (NCOG) study of @entity42870 , an ester of @entity5805 and @entity617 . All @entity1 had active disease and were refractory to standard alkylating agent chemotherapy. Treatment consisted of @entity42870 100 mg/m2/day orally for 3 consecutive days every 2 weeks. By strict response criteria used in this study there was one complete remission (CR), no partial remissions (PR), and three cases of clinical improvement (CI) in 18 evaluable @entity1 , for a total response rate of 22%. The median duration of response is 20+ months, with two @entity1 continuing to respond. @entity137 of this intermittent @entity42870 regimen consisted primarily of mild to moderate @entity882 and @entity1398 . No episodes of treatment-associated @entity281 or @entity548 occurred, and nonhematologic @entity137 was minor. Using strict response criteria, this study fails to confirm previous reports of high response rates for @entity42870 in @entity1 with @entity1072 refractory to standard therapy. The significance of the response category of clinical improvement in @entity1072 is demonstrated by the substantial improvement in objective parameters and the long duration of response. This study also emphasizes the need for standardization of response criteria for this disease.
